Your browser doesn't support javascript.
Rapid Improvement Following Receipt of Infliximab in Steroid-refractory Durvalumab-Associated Grade 3 Pneumonitis.
Huang, Sherri; Jordan, Aryanna; Jenneman, Dakota; Shafique, Michael; Holmstrom, Bjorn.
  • Huang S; Internal Medicine and Pediatrics, University of South Florida Morsani College of Medicine, Tampa, USA.
  • Jordan A; Internal Medicine, University of South Florida Morsani College of Medicine, Tampa, USA.
  • Jenneman D; Oncology, Levine Cancer Institute, Carolinas Medical Center, Tampa, USA.
  • Shafique M; Medical Oncology, Moffitt Cancer Center, Tampa, USA.
  • Holmstrom B; Internal Medicine, Moffitt Cancer Center, Tampa, USA.
Cureus ; 14(2): e22295, 2022 Feb.
Article in English | MEDLINE | ID: covidwho-1776615
ABSTRACT
Immune checkpoint inhibitors (ICIs) are important novel agents used in advanced non-small cell lung cancer (NSCLC) standard regimens; however, their use increases the risk of immune-related adverse effects (IRAEs). The incidence of IRAE pneumonitis is well documented in ICI use. Corticosteroids continue to be the mainstay of treatment for IRAEs. Here we report one of the first cases of using infliximab to treat durvalumab-associated pneumonitis.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report / Observational study / Prognostic study Language: English Journal: Cureus Year: 2022 Document Type: Article Affiliation country: Cureus.22295

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Case report / Observational study / Prognostic study Language: English Journal: Cureus Year: 2022 Document Type: Article Affiliation country: Cureus.22295